– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and.
Allakos Inc said on Tuesday
that it plans to discontinue studies testing its experimental
skin disease drug after it failed two mid-stage studies. The company also said it plans to cut.
Allakos Inc said on Tuesday
that it plans to discontinue the development of its experimental
skin disease drug after it failed two mid-stage studies. The company also said it aims to cut.
Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Company undergoes restructuring to focus on AK006, extending cash runway into mid-2026.
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy.